Michael E. Williams – författare

This book provides a comprehensive review of the primary industrial hygiene topics relevant to semiconductor processing: chemical and physical agents, and ventilation systems. The book also has excellent chapters on newer industrial hygiene concerns that are not specific to the semiconductor industry: ergonomics, indoor air quality, personal protective equipment, plan review, and records retention. While much of the information in these chapters can be applied to all industries, the focus and orientation is specific to issues in the semiconductor industry.

A full-length study of the influential role Tichenor played in shaping both the Baptist denomination and southern culture.Born in Spencer County, Kentucky, on November 11, 1825, Isaac Taylor Tichenor worked as a Confederate chaplain, a mining executive, and as president of the Agricultural and Mechanical College of Alabama (now Auburn University). He also served as corresponding secretary for the Home Mission Board of the Southern Baptist Convention in Atlanta from 1882 until 1899. In these capacities Tichenor developed the New South ideas that were incorporated into every aspect of his work and ultimately influenced many areas of southern life, including business, education, religion, and culture.In Isaac Taylor Tichenor: The Creation of the Baptist New South Michael E. Williams provides a comprehensive analysis of Tichenor’s life, examining the overall impact of his life and work. This volume also documents the methodologies Tichenor used to rally Southern Baptist support around its struggling Home Mission Board, which defined the makeup of the Southern Baptist Convention and defended the territory of the Convention.Tichenor was highly influential in forming a uniquely southern mindset prior to and at the turn of the century. Williams contends that Tichenor’s role in shaping Southern Baptists as they became the largest denomination in the South was crucial in determining their identity both the identities of the region and the SBC.

Major advances have occurred in the diagnosis and treatment of lymphoma in recent years. Our understanding of the molecular biology and genetics of the disease has increased exponentially, and significant imaging developments have resulted in earlier and more accurate diagnosis. The new edition of this landmark text places these advances in the context of daily clinical practice. Each chapter has been updated to reflect recent developments, including new treatment agents such as immunomodulatory drugs and the next generation of antibodies, and the increasing prognostic role of PET scanning. Results from recent large-scale clinical trials are presented, and pathology and cytogenetics are integrated into discussion of each disease entity, enabling the reader to review all the key diagnostic information in one place. Featuring many color illustrations, and written and edited by leading authorities in the field, Lymphoma provides all the information you need to diagnose and manage these complex disorders.

Major advances have occurred in the diagnosis and treatment of lymphoma in recent years. Our understanding of the molecular biology and genetics of the disease has increased exponentially, and significant imaging developments have resulted in earlier and more accurate diagnosis. The new edition of this landmark text places these advances in the context of daily clinical practice. Each chapter has been updated to reflect recent developments, including new treatment agents such as immunomodulatory drugs and the next generation of antibodies, and the increasing prognostic role of PET scanning. Results from recent large-scale clinical trials are presented, and pathology and cytogenetics are integrated into discussion of each disease entity, enabling the reader to review all the key diagnostic information in one place. Featuring many color illustrations, and written and edited by leading authorities in the field, Lymphoma provides all the information you need to diagnose and manage these complex disorders.

After a decade of tremendous progress in the diagnostic and therapeutic approaches to malignant lymphoma, optimal treatment strategies are now based not only on accurate diagnosis but also on thorough evaluation of clinical and molecular risk factors. Even more importantly, molecular targeted approaches have been shown to be effective in the treatment of distinct lymphoma subtypes. Against this background, clinical management of especially the rare lymphomas remains a challenge for the general oncologist. This book provides a comprehensive overview of current treatment strategies in these rare lymphoma subtypes. Experts in the field from around the world describe histomorphology in a clinically relevant manner, consider the role of risk factors in detail, and discuss the spectrum of therapeutic approaches. Special emphasis is placed on the translation of molecular science into clinical care, and a disease-specific algorithm is proposed for each entity.

After a decade of tremendous progress in the diagnostic and therapeutic approaches to malignant lymphoma, optimal treatment strategies are now based not only on accurate diagnosis but also on thorough evaluation of clinical and molecular risk factors. Even more importantly, molecular targeted approaches have been shown to be effective in the treatment of distinct lymphoma subtypes. Against this background, clinical management of especially the rare lymphomas remains a challenge for the general oncologist. This book provides a comprehensive overview of current treatment strategies in these rare lymphoma subtypes. Experts in the field from around the world describe histomorphology in a clinically relevant manner, consider the role of risk factors in detail, and discuss the spectrum of therapeutic approaches. Special emphasis is placed on the translation of molecular science into clinical care, and a disease-specific algorithm is proposed for each entity.

After a decade of tremendous progress in the diagnostic and therapeutic approaches to malignant lymphoma, optimal treatment strategies are now based not only on accurate diagnosis but also on thorough evaluation of clinical and molecular risk factors. Even more importantly, molecular targeted approaches have been shown to be effective in the treatment of distinct lymphoma subtypes. Against this background, clinical management of especially the rare lymphomas remains a challenge for the general oncologist. This book provides a comprehensive overview of current treatment strategies in these rare lymphoma subtypes. Experts in the field from around the world describe histomorphology in a clinically relevant manner, consider the role of risk factors in detail, and discuss the spectrum of therapeutic approaches. Special emphasis is placed on the translation of molecular science into clinical care, and a disease-specific algorithm is proposed for each entity.